6617.TWO
Price:
$112.5
Market Cap:
$14.02B
Gongwin Biopharm Holdings Co., Ltd., a clinical-stage biopharmaceutical company, develops anticancer drugs. It is developing PTS302, which has completed Phase III clinical trials for the treatment of lung cancer; PTS100, which is in Phase II clinical trials for the treatment of liver cancer; PTS-02 for the treatment of adenoid cystic carcinoma; and PTS500 for the treatment of malignant pleural effusion. The company was founded in 2014 and is based in Taipei, Taiwan.
Industry
Medical - Distribution
IPO Date
2017-02-08
Stock Exchange
TWO
Ticker
6617.TWO
According to Gongwin Biopharm Holdings Co., Ltd.’s latest financial reports and current stock price. The company's current PE Ratio is -204.55. This represents a change of -10.40% compared to the average of -228.30 of the last 4 quarters.
The mean historical PE Ratio of Gongwin Biopharm Holdings Co., Ltd. over the last ten years is -187.22. The current -204.55 PE Ratio has changed 10.83% with respect to the historical average. Over the past ten years (40 quarters), 6617.TWO's PE Ratio was at its highest in in the December 2022 quarter at -82.61. The PE Ratio was at its lowest in in the March 2023 quarter at -419.74.
Average
-187.22
Median
-195.69
Minimum
-270.52
Maximum
-72.46
Discovering the peaks and valleys of Gongwin Biopharm Holdings Co., Ltd. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 273.35%
Maximum Annual PE Ratio = -72.46
Minimum Annual Increase = -46.12%
Minimum Annual PE Ratio = -270.52
Year | PE Ratio | Change |
---|---|---|
2024 | -166.08 | -26.29% |
2023 | -225.31 | 65.44% |
2022 | -136.19 | -46.12% |
2021 | -252.77 | -6.56% |
2020 | -270.52 | 273.35% |
The current PE Ratio of Gongwin Biopharm Holdings Co., Ltd. (6617.TWO) is less than than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
-175.86
5-year avg
-210.17
10-year avg
-187.22
Gongwin Biopharm Holdings Co., Ltd.’s PE Ratio is
Company | PE Ratio | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Gongwin Biopharm Holdings Co., Ltd. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Gongwin Biopharm Holdings Co., Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Gongwin Biopharm Holdings Co., Ltd.'s PE Ratio?
How is the PE Ratio calculated for Gongwin Biopharm Holdings Co., Ltd. (6617.TWO)?
What is the highest PE Ratio for Gongwin Biopharm Holdings Co., Ltd. (6617.TWO)?
What is the 3-year average PE Ratio for Gongwin Biopharm Holdings Co., Ltd. (6617.TWO)?
What is the 5-year average PE Ratio for Gongwin Biopharm Holdings Co., Ltd. (6617.TWO)?
How does the current PE Ratio for Gongwin Biopharm Holdings Co., Ltd. (6617.TWO) compare to its historical average?